JAK2 V617F mutation was present in over 95% of patients with PV and in approximately half of patients with ET and PMF [8]; and moreover, in 2008, the Word Health Organization included its detection as diagnostic criteria for MPN [9]. Here, JAK2 is linked to myeloproliferative neoplasm.